Skip to content

Top-Line: Upadacitinib in Ulcerative Colitis Vodcast Survey

On behalf of the AbbVie Rheumatology team, we hope you found this vodcast both enjoyable and professionally beneficial.

We strive for continual improvement of our educational initiatives and value your feedback.  Thank you for taking time to answer the questions below.
 
AbbVie Pty Ltd, Mascot NSW, Australia. ABBV-AU-00072-E. OCT 2022.
1.Did this video podcast address your query on the benefit-risk profile of upadacitinib in ulcerative colitis?(Required.)
2.Overall, how would you rate this video podcast?(Required.)
3.How relevant are the topics discussed by the panel to your clinical practice?(Required.)
4.How important to your clinical practice are the learnings from this recording?(Required.)
5.Would you recommend this video podcast to a colleague?(Required.)
6.OPTIONAL – If you have any other feedback, or suggestions regarding topics for future GRID medical education initiatives, please let us know!
Current Progress,
0 of 6 answered